International Clinical Trial: Arsenic Trioxide Combined with Cyclosporine A and Stanozolol Versus Cyclosporine A and Stanozolol for the Treatment of Newly Diagnosed Non-Severe Aplastic Anemia

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128749) titled 'Arsenic Trioxide Combined with Cyclosporine A and Stanozolol Versus Cyclosporine A and Stanozolol for the Treatment of Newly Diagnosed Non-Severe Aplastic Anemia' on July 24.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Henan Cancer Hospital

Condition: Initial diagnosis of non-severe aplastic anemia

Intervention: Control group: Cyclosporine A and Stanozolol:CsA at a dose of 3 to 5mg/(kg·d) should be taken orally in two divided doses. Blood drug concentration should be monitored two weeks later, and then once a month. The dosage should be appropriately adjusted to maintain th...